Scottish Medicines Consortium cabozantinib (Cabometyx)

Ref: SMC

in the absence of a submission from the holder of the marketing authorisation:

cabozantinib (Cabometyx) is not recommended for use within NHSScotland.

Indication under review: As monotherapy for the treatment of hepatocellular carcinoma in adults who have previously been treated with sorafenib.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.